Skip to main content
HEM Pharma Inc. (KOSDAQ:376270)
South Korea flag South Korea · Delayed Price · Currency is KRW
59,500
-1,500 (-2.46%)
At close: Apr 28, 2026

HEM Pharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2025 FY 2024
Period Ending
 Dec '25 Dec '24
Operating Revenue
12,97915,067
Other Revenue
--0
Revenue
12,97915,067
Revenue Growth (YoY)
-13.86%-
Cost of Revenue
12,35513,452
Gross Profit
624.021,616
Selling, General & Admin
11,4835,566
Research & Development
3,8403,212
Amortization of Goodwill & Intangibles
321.92183.63
Other Operating Expenses
167.28107.99
Operating Expenses
16,2079,297
Operating Income
-15,583-7,682
Interest Expense
-649.13-261.78
Interest & Investment Income
308.57232.77
Currency Exchange Gain (Loss)
-8.0343.26
Other Non Operating Income (Expenses)
-7,27731.82
EBT Excluding Unusual Items
-23,209-7,636
Gain (Loss) on Sale of Investments
30.4724.89
Gain (Loss) on Sale of Assets
-7.02-
Asset Writedown
-534.93-
Pretax Income
-23,720-7,611
Income Tax Expense
3.6235.34
Earnings From Continuing Operations
-23,724-7,646
Minority Interest in Earnings
-118.36-
Net Income
-23,842-7,646
Net Income to Common
-23,842-7,646
Shares Outstanding (Basic)
76
Shares Outstanding (Diluted)
76
Shares Change (YoY)
10.69%-
EPS (Basic)
-3389.00-1203.00
EPS (Diluted)
-3389.00-1203.00
Free Cash Flow
-18,100-12,367
Free Cash Flow Per Share
-2572.76-1945.77
Gross Margin
4.81%10.72%
Operating Margin
-120.06%-50.98%
Profit Margin
-183.69%-50.75%
Free Cash Flow Margin
-139.45%-82.08%
EBITDA
-12,989-5,259
EBITDA Margin
-100.07%-34.91%
D&A For EBITDA
2,5952,422
EBIT
-15,583-7,682
EBIT Margin
-120.06%-50.98%
Advertising Expenses
3,16351.21
Source: S&P Capital IQ. Standard template. Financial Sources.